Hyperthyroidism: Methimazole Plus L-carnitine and Selenium

Association of Methimazole With L-carnitine and Selenium in Patients With Hyperthyroidism

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04946123

Enrollment

Registered

2021-06-30

Start date

2021-07-05

Completion date

2025-06-04

Last updated

2025-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperthyroidism

Brief summary

The study aims to investigate the benefits of methimazole treatment in patients with hyperthyroidism, associated with supplementation of L-carnitine and Selenium.

Interventions

DIETARY_SUPPLEMENTL-carnitine+Selenium

Supplementation with L-carnitine and Selenium

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of hyperthyroidism requiring therapy with methimazole

Exclusion criteria

* Drug and alcohol abuse; * Pregnancy; * Medically uncontrolled psychiatric conditions; * Interfering therapies (lithium, interferone, TKI, amiodarone)

Design outcomes

Primary

Measure	Time frame	Description
Hyperthyroidism symptoms	Change from baseline QoL at 6 months of supplementation	Improvement of the patients' quality of life through questionnaire

Secondary

Measure	Time frame	Description
TRAb	Four time points: baseline; after 3 months of supplementation; after 6 months of supplementation; end of the study (12 months)	Change in serum TRAb (TSH receptor antibodies)
TSH	Four time points: baseline; after 3 months of supplementation; after 6 months of supplementation; end of the study (12 months)	Change in serum TSH (Thyroid stimulating hormone)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026